▎药明康德/报导
药明康德董事长李革博士荣获CPhI“2019年度CEO”
2019年11月11日——全球闻名的国际制药质料博览会（CPhI）日前发布2019年度奖项（CPhI Pharma Awards）评选成果，药明康德董事长兼首席执行官李革博士凭仗为全球生物医疗研制范畴做出的杰出奉献，荣获“年度CEO”称谓。
CPhI是国际上最大的医药职业盛会之一，本年的CPhI全球大会（CPhI Worldwide）招引了超越45,000名业内人士参会。CPhI年度奖项旨在赞誉那些持之以恒、开拓立异，为推进职业开展做出重要奉献的企业与个人。奖项评定委员会独立客观，由全球多位资深专家组成。
评委会表明，在李革博士的带领下，药明康德已成为全球医药立异范畴备受爱崇的赋能者，为医疗健康职业的开展做出了杰出的奉献。现在，药明康德开放式、一体化赋能渠道正承载着全球30多个国家，3700多个合作伙伴的研制立异项目，不断加快新药研制进程，为患者带来突破性的医治计划。
“我很快乐获此荣誉，也特别感谢评委会对药明康德全球化赋能渠道的认可，”药明康德董事长兼首席执行官李革博士表明，“咱们十分侥幸能够协助全球立异合作伙伴提高研制功率，让更多新药、好药提前进入市场，谋福全球病患。”
关于药明康德
药明康德（股票代码：603259.SH/2359.HK）为全球生物医药职业供给全方位、一体化的新药研制和出产服务。经过赋能全球制药、生物科技和医疗器械公司，药明康德致力于推进新药研制进程，为患者带来突破性的治疗计划。本着以研讨为首任，以客户为中心的主旨，药明康德经过超高的性价比和高效的研制服务，助力客户提高研制功率，服务范围包括化学药研制和出产、细胞及基因疗法研制出产、医疗器械测验等范畴。现在，药明康德的赋能渠道正承载着来自全球30多个国家的3700多家合作伙伴的研制立异项目，致力于将更多新药、好药带给全球病患，提前完成“让天下没有难做的药，难治的病”的愿景。更多信息，请拜访公司网站：ess capabilities and services, accelerating the discovery and development of new medicines for patients around the world.”
“I’m honored by this award and its recognition of WuXi’s global platform,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “It’s been our great privilege to serve our innovative partners around the world and help bring some of the most needed medicines closer to patients.”
about WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,700 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated." Please visit: http://.
